SSY GROUP (02005) announced that its upadacitinib has been approved by China's National Medical Products Administration for registration as an active pharmaceutical ingredient in marketed preparations. This makes the company the third domestic enterprise to receive such approval. Upadacitinib is a JAK-1 inhibitor primarily used to treat rheumatoid arthritis, Crohn's disease, atopic dermatitis, psoriatic arthritis, ulcerative colitis, and giant cell arteritis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments